Transition Bio operates the Condensomics™ platform, a microfluidics-driven system that generates proprietary high-throughput data to map biomolecular condensates. The company applies a physics-first approach and machine learning to enable condensate target identification and small-molecule drug discovery. Transition Bio recently closed a $50 million Series A financing to accelerate its platform and translational efforts. The funding will be used to scale up the technology and translate the science across a variety of targets and disease areas. The company launched in September 2020 and maintains teams in the U.S. and U.K., with announcements listing Cambridge, Mass. and Cambridge, England. Recent corporate developments include hiring Shilpi Arora as senior vice president of discovery research and board additions from its new investors. Transition Bio was formed and launched to build technological capabilities for evaluating and advancing the study of biomolecular condensates, branded internally as Condensomics™. The company intends to replace the industry’s reliance on conventional technologies for studying condensates by deploying unique physical-science methods, microfluidics, and big-data approaches. Transition Bio aims to be the world leader in discovery, analysis, and modulation of biological condensates and to generate hypothesis-free drug development opportunities. Its research organization is led by Assaf Rotem, Ph.D., with scientific teams based in Cambridge, MA (the company’s headquarters) and Cambridge, UK. Founding scientific leadership includes Professor David Weitz (Harvard) and Professor Tuomas Knowles (University of Cambridge). The company recently completed an initial close of its Series Seed financing at the end of September, led by Lifeforce Capital.

Total raised

$50M

Funding rounds

2

Latest round

Series A

Latest activity

Jun 2022